1.00
+0.0084(+0.85%)
Currency In USD
| Previous Close | 0.99 |
| Open | 1 |
| Day High | 1.03 |
| Day Low | 0.97 |
| 52-Week High | 1.51 |
| 52-Week Low | 0.33 |
| Volume | 940,188 |
| Average Volume | 741,636 |
| Market Cap | 100.36M |
| PE | -3.45 |
| EPS | -0.29 |
| Moving Average 50 Days | 1 |
| Moving Average 200 Days | 0.91 |
| Change | 0.01 |
If you invested $1000 in Oncolytics Biotech Inc. (ONCY) 10 years ago, it would be worth $389.11 as of January 14, 2026 at a share price of $1. Whereas If you bought $1000 worth of Oncolytics Biotech Inc. (ONCY) shares 5 years ago, it would be worth $348.43 as of January 14, 2026 at a share price of $1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
GlobeNewswire Inc.
Jan 12, 2026 2:00 PM GMT
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN DIEGO, Jan. 12, 2026 (GLOBE NEW
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
GlobeNewswire Inc.
Jan 09, 2026 2:00 PM GMT
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided additional context regarding its previously announced